TRIZIVIR Drug Patent Profile

Which patents cover Trizivir, and when can generic versions of Trizivir launch?

Trizivir is a drug marketed by Viiv Hlthcare and is included in one NDA.

The generic ingredient in TRIZIVIR is abacavir sulfate; lamivudine; zidovudine. There are twelve drug master file entries for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.

Summary for TRIZIVIR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	20
Drug Prices:	Drug price information for TRIZIVIR
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRIZIVIR
What excipients (inactive ingredients) are in TRIZIVIR?	TRIZIVIR excipients list
DailyMed Link:	TRIZIVIR at DailyMed

See drug prices for TRIZIVIR

Recent Clinical Trials for TRIZIVIR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute of Allergy and Infectious Diseases (NIAID)	Phase 3
AIDS Clinical Trials Group	Phase 3
Ines Perez	Phase 4

See all TRIZIVIR clinical trials

Paragraph IV (Patent) Challenges for TRIZIVIR

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRIZIVIR	Tablets	abacavir sulfate; lamivudine; zidovudine	300 mg/150 mg/ 300 mg	021205	1	2011-03-22

US Patents and Regulatory Information for TRIZIVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000		DISCN	Yes	No

Expired US Patents for TRIZIVIR

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000	6,417,191*PED
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000	4,724,232
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000	6,180,639*PED
Viiv Hlthcare	TRIZIVIR	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	021205-001	Nov 14, 2000	7,119,202*PED

International Patents for TRIZIVIR

When does loss-of-exclusivity occur for TRIZIVIR?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRIZIVIR around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	69622386
Denmark	0382526
Australia	3702589
Hungary	0002754

Supplementary Protection Certificates for TRIZIVIR

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0817637	23/2005	Austria		PRODUCT NAME: KOMBINATION, UMFASSEND ABACAVIR BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES ESTERS ODER SOLVAT DAVON UND LAMIVUDIN BZW. EIN PHYSIOLOGISCH AKZEPTABLES SALZ, ESTER, SALZ DES; REGISTRATION NO/DATE: EU/1/04/298/001, EU/1/04/298/002 20041217
0434450	1999C0033	Belgium		PRODUCT NAME: ABACAVIR SULFATE; NATL. REGISTRATION NO/DATE: EU/1/99/112/001 19990708; FIRST REGISTRATION: CH 55048 19990628
0382526	SPC/GB96/043	United Kingdom		PRODUCT NAME: LAMIVUDINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: CH 53662 19960228; CH 53663 19960228; UK EU/1/96/015/001 19960808; UK EU/1/96/015/002 19960808
0817637	CA 2005 00028	Denmark

TRIZIVIR Market Analysis and Financial Projection

Last updated: February 12, 2026

What Are the Market Dynamics for Trizivir?

Trizivir is a fixed-dose combination antiretroviral medication used to treat HIV/AIDS. Its composition includes abacavir, lamivudine, and zidovudine. Approved by the FDA in 2000, it was once a key component in HIV therapy but has experienced declining demand over recent years.

Market size and share:
Globally, the HIV medication market was valued at approximately $31 billion in 2022; Trizivir held a minimal share due to declining use and better alternatives. In the U.S., the number of HIV-positive individuals is around 1.2 million, with approximately 65% on combination antiretroviral therapy (cART). The US market accounts for 45% of global HIV drug sales.

Demand trends:

• The use of fixed-dose combination therapies like Trizivir has decreased, replaced by newer medications with improved safety profiles and fewer side effects.
• Treatment guidelines favor integrase strand transfer inhibitors (INSTIs) and other modern regimens, reducing reliance on older drugs like Trizivir.
• Pricing pressures and patent expiration influence market dynamics, encouraging the shift toward generic and novel therapies.

Competitive landscape:

• Major players: Gilead Sciences, ViiV Healthcare, Johnson & Johnson.
• Alternative therapies: Biktarvy (Gilead), Tivicay (Gilead), and Dolutegravir-based regimens dominate the market.
• Generics have entered markets in various regions, further reducing Trizivir’s market share.

Regulatory and policy factors:

• The FDA has not approved new indications for Trizivir in years; promotional efforts are minimal.
• Global initiatives seek affordable treatments, favoring generics over patented drugs.
• Some countries include Trizivir in their essential medicines list, but the overall market remains small.

What Is the Financial Trajectory for Trizivir?

Revenue trends:

• GSK, which owns the rights to Trizivir, reported declining revenues from the drug since the early 2010s.
• In 2020, Trizivir's sales in the U.S. were projected to be significantly below peak figures, which historically exceeded $300 million annually during the early 2000s.

Patent status and generics:

• Patent expiry occurred in 2014 for some formulations; generic versions entered markets in the U.S., India, and Europe.
• Patent protections in certain regions extend to 2025, but market penetration by generics limits potential growth.

Manufacturing costs:

• Fixed-dose combination drugs like Trizivir have moderate manufacturing costs relative to newer therapies but face cost reductions due to generic competition.
• Pricing pressures decrease profit margins, especially in emerging markets where price sensitivity is high.

Market exit potential:

• Given current treatment standards and declining demand, GSK has signaled minimal investment in marketing or R&D for Trizivir.
• The drug is likely to be phased out or maintained solely as a generic option until patent expiration and market withdrawal occur.

Investment and R&D implications:

• No recent R&D efforts or pipeline development focus on Trizivir.
• R&D investments favor newer drugs targeting drug-resistant HIV strains or improved safety profiles.
• The financial trajectory suggests a decline toward market exit over the next 2–3 years in most regions.

Key Takeaways

• MarketDemand: Trizivir faces declining demand due to evolving HIV treatment guidelines favoring newer, safer therapies.
• Market Share: Its global market share has diminished; generics and competitors dominate the HIV medication landscape.
• Revenue: Sales have significantly declined from peak figures in the early 2000s, with revenues trending toward minimal levels.
• Patent Status: Patent expiry facilitates generic competition, further limiting profitability.
• Future Outlook: The drug is expected to be phased out in mature markets, with minimal sales remaining during the patent expiration period.

FAQs

What is the primary reason for the decline in Trizivir sales?
The shift to newer antiretroviral regimens with better safety profiles and simplified dosing has reduced Trizivir’s relevance.

Are there ongoing patent protections for Trizivir?
Patents largely expired or are expiring between 2023-2025, leading to generic availability and reduced sales.

Does GSK plan to develop new formulations of Trizivir?
No, current strategies prioritize newer antiretroviral agents over reformulation or development of Trizivir.

Who are the main competitors replacing Trizivir?
Gilead’s Biktarvy and Tivicay, along with other integrase inhibitor-based regimens, dominate the market.

Will Trizivir be phased out globally?
Likely, especially in regions with access to advanced therapies and generic options, but some markets might retain it as a low-cost alternative until patent expiry.

---

Sources:
[1] IQVIA. Global HIV Therapy Market Data, 2022.
[2] FDA. Trizivir Approval and Patent Status.
[3] GSK Annual Reports, 2022.
[4] CDC. HIV Treatment Guidelines, 2023.
[5] Bloomberg Intelligence. HIV Drugs Market Analysis, 2023.